Exosome-Based Multiplex Biomarker Panels for Severe Eye Disease
Our Innovative Technology Platform
ExOcular tests isolate exosomes and measure eye disease-specific biomarkers. Our multiplex panels provide physicians and eye care providers with insights into a patient's risk of vision-threatening diseases, facilitate easy tracking of disease progression, and monitor treatment effectiveness.
Measure Biomarkers
Multiplex panels of disease-specific biomarkers isolated from exosomes
Inform Care
Identify and treat high-risk patients earlier. Optimize referrals.
Improve Outcomes
Personalize treatment plan. Reduce unnecessary procedures.
The Problem for Physicians and Patients
Eye imaging tools lack the prognostic accuracy needed to measure progression risk or to personalize treatment. Patients often underestimate the urgency of seeking a comprehensive eye exam. Late visits to ophthalmologists may result in one eye progressing beyond effective treatment. This inadequacy leaves both patients and providers grappling with alarming unanswered questions and consequences.
How Bad
Are My
Eyes?
Is the disease clinically significant?
What Happens Next?
How aggressive is the disease?
Am I Going to Go Blind?
What can be done to prevent or delay blindness?
Our Solution
Our multiplex biomarker panels provide insights to preserve vision.
Early Diagnosis
Primary care workflow includes blood tests, making it straightforward for physicians to order an exosome-based blood test alongside routine blood tests. This diagnostic information can help optimize referrals to ophthalmologists.
Progression Prognosis
Currently, no procedure categorizes patients at risk of progressing to vision-threatening diseases. A prognostic test providing a Disease Severity Score could guide early intervention.
Treatment Monitoring
Once therapy begins, serial testing can optimize dosing schedules and indicate if medications need to change. This strategy personalizes treatment, enhances health outcomes and saves costs on ineffective specialty drugs.
The Problem for Pharma Companies
Clinical development professionals are charged with executing clinical trials. These scientists need objective biomarkers to risk stratify patients, reflect changes in disease progression and treatment response. Their ultimate goals are to meet timelines and budgets, advance the most promising drug candidates and filter out candidates that are unlikely to demonstrate efficacy.
Client Objectives & Biomarker Utility
Bring New Drugs to Market
On Time and On Budget
Enrich Clinical Trials
Monitor Treatment Efficacy
Our Solution
Clinical Trial Enrichment
Our prognostic panels categorize patients from low to high risk for progression to vision-threatening disease. Pharma may design the trial to enroll high-risk participants to amplify treatment effects. This approach can tailor the number of subjects needed for endpoints and accelerate time to market.
Therapy Monitoring
For late-stage disease participants, our products assist in dose titration and therapy efficacy monitoring. Objective efficacy results can decrease follow-up times and enrollment requirements, accelerating time to market.